Kairos Pharma, Ltd. (KAPA)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $1.38M
Last updated: Nov 17, 2026 at 4:10 PM ET
Kairos Pharma, Ltd. (KAPA) Statistics
Kairos Pharma (KAPA) has a market cap of $1.38M. Its share count is up 711.92% from a year earlier. It holds $3.13M more cash than debt, 226.86% of its market cap.
Total Valuation
| Market Cap | $1.38M |
|---|---|
| Latest price (Nov 17, 2026) | $0.39 |
Key Dates
| Last Earnings Date | Nov 13, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is down 93.22% over 52 weeks and trades 61.76% below its 50-day average.
| Beta (1Y) | 1.57 |
|---|---|
| 52-Week Change | -93.22% |
| 1-Month Change | -30.92% |
| 3-Month Change | -81.83% |
| 6-Month Change | -88.23% |
| Total Return (1Y) | -93.22% |
| Max Drawdown (1Y) | -94.20% |
| Max Drawdown (3Y) | -97.84% |
| Sharpe Ratio (1Y) | -2.85 |
| Correlation with SPY (1Y) | 0.24 |
| 50-Day Average | $1.02 |
| 200-Day Average | $2.75 |
| 52-Week Range | $0.41 to $7.28 |
| RSI (14 Days) | 24.2 |
| Average Volume (20 Days) | 68.11K |
Financial Position
Current assets cover 6.77x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.77x |
|---|---|
| Quick Ratio | 6.77x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -164.93% and return on assets is -146.25% over the last 12 months.
| Return on Equity (ROE) | -164.93% |
|---|---|
| Return on Assets (ROA) | -146.25% |
Scores
KAPA has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | $120.00K |
| Operating Income | -$6.53M |
| Pretax Income | -$6.39M |
| Net Income | -$6.39M |
| EBITDA | -$5.57M |
| Reported EPS (TTM) | -$1.28 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 88.79% of the $4.37M in total assets.
| Cash and Equivalents | $3.13M |
|---|---|
| Total Debt | $0 |
| Net Cash | $3.13M |
| Net Cash Per Share | $0.93 |
| Working Capital | $2.85M |
| Shareholder Equity | $3.88M |
| Book Value Per Share | $1.16 |
| Total Assets | $4.37M |
| Total Liabilities | $495.00K |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$4.11M |
|---|---|
| FCF Per Share | -$1.46 |
| Depreciation and Amortization | $959.00K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
KAPA does not pay a dividend.
| Buyback Yield | -141.79% |
|---|---|
| Shareholder Yield | -141.79% |
Stock Splits
The last split was a 1-for-7 reverse split on Sep 1, 2026.
| Last Split Date | Sep 1, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:7 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About KAPA
What is KAPA's market cap?
Kairos Pharma has a market cap of $1.38M.
How many shares of KAPA are outstanding?
Kairos Pharma has 3.35M shares outstanding. The count is up 711.92% from a year earlier.
Does KAPA pay a dividend?
No. Kairos Pharma does not pay a dividend.
How much debt does KAPA have?
Kairos Pharma has $0 of total debt and $3.13M of cash and equivalents, a net cash position of $3.13M.
KAPA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors